EpiAxis Therapeutics clinical trial validates targeting LSD1 inhibition
EpiAxis Therapeutics has announced the results of its pioneering clinical trial EPI-PRIMED, the first time that an epigenetic inhibitor has been used in combination with chemotherapy to treat metastatic cancer. The purpose of the EPI-PRIMED study was to investigate...
EpiAxis executives attend US biotech conferences
It's an exciting month for EpiAxis Therapeutics as we return to face-to-face biotech conferences after more than two years of virtual attendance. Chairman Dr David Fuller is currently representing EpiAxis at the ASCO 2022 Annual Meeting in Chicago; while CEO Dr Jeremy...
EpiAxis Therapeutics presents at Bioshares Biotech Summit
EpiAxis Therapeutics was pleased to attend and present at the 16th Bioshares Biotech Summit this month in Albury, NSW. BioShares is a life science conference mainly targeting ASX-listed Australian biotech companies, biotech investors, fund managers and brokers and...
There is currently no therapy to fight recurrent, metastatic breast cancer, which is the major source of death in women with breast cancer. Furthermore, current first-line treatments have extensive side-effects.We are determined to fix that.
Professor Sudha Rao
Founder at EpiAxis Therapeutics